Organogenesis Holdings Company Leadership
| ORGO Stock | USD 4.04 0.01 0.25% |
Organogenesis Holdings employs about 862 people. The company is managed by 10 executives with a total tenure of roughly 2012 years, averaging almost 201.0 years of service per executive, having 86.2 employees per reported executive. Analysis of Organogenesis Holdings' management performance can provide insight into the firm performance.
Organogenesis |
Organogenesis Holdings' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Organogenesis Holdings' future performance. Based on our forecasts, it is anticipated that Organogenesis will maintain a workforce of about 860 employees by December 2024.Organogenesis Holdings Management Team Effectiveness
The company has return on total asset (ROA) of 0.0164 % which means that it generated a profit of $0.0164 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0266) %, meaning that it created substantial loss on money invested by shareholders. Organogenesis Holdings' management efficiency ratios could be used to measure how well Organogenesis Holdings manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to grow to 0.01. Also, Return On Capital Employed is likely to grow to 0.03. At this time, Organogenesis Holdings' Return On Assets are very stable compared to the past year. As of the 26th of November 2024, Asset Turnover is likely to grow to 1.20, while Total Assets are likely to drop about 292.5 M.As of the 26th of November 2024, Net Income Applicable To Common Shares is likely to grow to about 18.8 M, while Common Stock Shares Outstanding is likely to drop about 105.4 M.
Organogenesis Holdings Workforce Comparison
Organogenesis Holdings is regarded fifth in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 9,921. Organogenesis Holdings holds roughly 862 in number of employees claiming about 9% of equities under Health Care industry.
Organogenesis Holdings Profit Margins
The company has Profit Margin (PM) of (0.02) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.05 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.05.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.58 | 0.7152 |
|
|
Organogenesis Holdings Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Organogenesis Holdings insiders, such as employees or executives, is commonly permitted as long as it does not rely on Organogenesis Holdings' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Organogenesis Holdings insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-03-01 | 0.8261 | 19 | 23 | 4,398,190 | 787,960 |
| 2023-03-01 | 1.5 | 18 | 12 | 5,656,559 | 45,809 |
| 2022-09-01 | 2.0 | 2 | 1 | 8,000 | 805.00 |
| 2022-06-01 | 0.451 | 23 | 51 | 1,812,876 | 3,446,974 |
| 2022-03-01 | 2.1 | 21 | 10 | 2,791,398 | 112,419 |
| 2021-12-01 | 4.4 | 22 | 5 | 25,725,946 | 25,650,906 |
| 2021-09-01 | 0.8333 | 5 | 6 | 317,000 | 600,000 |
| 2021-06-01 | 0.5238 | 11 | 21 | 39,106,747 | 77,500,526 |
| 2021-03-01 | 1.2222 | 22 | 18 | 1,035,202 | 1,144,197 |
| 2020-12-01 | 16.0 | 16 | 1 | 7,015,668 | 200,000 |
| 2020-09-01 | 0.3333 | 1 | 3 | 15,000 | 42,188 |
| 2020-06-01 | 16.0 | 16 | 1 | 1,829,168 | 1,150 |
| 2020-03-01 | 3.0 | 6 | 2 | 970,699 | 428,350 |
| 2019-12-01 | 2.0 | 2 | 1 | 6,000,667 | 667.00 |
| 2019-09-01 | 31.0 | 31 | 1 | 3,574,704 | 4,100,000 |
| 2018-12-01 | 1.0976 | 45 | 41 | 53,336,946 | 10,943,827 |
| 2017-09-01 | 1.0 | 1 | 1 | 186,320 | 186,320 |
| 2016-12-01 | 0.0909 | 1 | 11 | 186,320 | 8,942,570 |
Organogenesis Holdings Notable Stakeholders
An Organogenesis Holdings stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Organogenesis Holdings often face trade-offs trying to please all of them. Organogenesis Holdings' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Organogenesis Holdings' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Gary Sr | CEO, President | Profile | |
| BA Esq | VP Counsel | Profile | |
| Patrick Bilbo | Chief Officer | Profile | |
| Thomas Pearl | Vice Resources | Profile | |
| Zorina Pitkin | VP Systems | Profile | |
| Brian Grow | Chief Officer | Profile | |
| Kurt Matheson | VP Marketing | Profile | |
| David Francisco | Chief Officer | Profile | |
| William CPA | Secretary | Profile | |
| Robert Cavorsi | Vice Strategy | Profile |
About Organogenesis Holdings Management Performance
The success or failure of an entity such as Organogenesis Holdings often depends on how effective the management is. Organogenesis Holdings management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Organogenesis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Organogenesis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.01 | 0.01 | |
| Return On Capital Employed | 0.03 | 0.03 | |
| Return On Assets | 0.01 | 0.01 | |
| Return On Equity | 0.02 | 0.02 |
Organogenesis Holdings Workforce Analysis
Traditionally, organizations such as Organogenesis Holdings use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Organogenesis Holdings within its industry.Organogenesis Holdings Manpower Efficiency
Return on Organogenesis Holdings Manpower
| Revenue Per Employee | 502.5K | |
| Revenue Per Executive | 43.3M | |
| Net Income Per Employee | 5.7K | |
| Net Income Per Executive | 494.5K | |
| Working Capital Per Employee | 167.7K | |
| Working Capital Per Executive | 14.5M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organogenesis Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organogenesis Holdings. If investors know Organogenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organogenesis Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 3.5 | Earnings Share (0.05) | Revenue Per Share 3.446 | Quarterly Revenue Growth 0.061 | Return On Assets 0.0164 |
The market value of Organogenesis Holdings is measured differently than its book value, which is the value of Organogenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Organogenesis Holdings' value that differs from its market value or its book value, called intrinsic value, which is Organogenesis Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organogenesis Holdings' market value can be influenced by many factors that don't directly affect Organogenesis Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organogenesis Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Organogenesis Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organogenesis Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.